Skip to content
Diario M茅dico路 @diariomedico 路 X路路 20 hours agoScore70
Body

馃珌#ESMO26 I Divarasib reduce el riesgo de muerte un 44% en c谩ncer de #pulm贸n con KRAS G12C frente a las terapias actuales.

馃憠馃徎Con el f谩rmaco de @Roche_es la mediana de supervivencia global fue de 17,7 meses con divarasib, frente a 12,0 meses con Sotor... https://www.diariomedico.com/medicina/oncologia/divarasib-reduce-riesgo-muerte-44-cancer-pulmon-kras-g12c-frente-terapias-actuales.html?utm_medium=Social&utm_source=Twitter#Echobox=1792918328

36 views 路 0 likes 路 0 reposts 路 0 replies

Source: Diario M茅dico 路 x.com

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org

Disclaimer CBA Frontier Insights uses AI-assisted methods to aggregate, summarize, and analyze publicly accessible biopharmaceutical information. Content is provided for informational and educational purposes only and does not represent the official views of original sources or affiliated organizations. AI-generated content may contain errors; please verify important information against primary sources. Intellectual property rights remain with their respective owners. For copyright concerns or corrections, please contact us through the website鈥檚 feedback page.